Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 25 studies | 33% ± 17% | |
fibroblast | 17 studies | 24% ± 6% | |
smooth muscle cell | 15 studies | 30% ± 10% | |
endothelial cell | 11 studies | 30% ± 11% | |
plasmacytoid dendritic cell | 11 studies | 28% ± 11% | |
astrocyte | 9 studies | 37% ± 16% | |
myofibroblast cell | 8 studies | 24% ± 8% | |
basal cell | 8 studies | 21% ± 5% | |
microglial cell | 7 studies | 25% ± 8% | |
adipocyte | 7 studies | 23% ± 4% | |
type I pneumocyte | 6 studies | 23% ± 5% | |
Mueller cell | 6 studies | 32% ± 10% | |
glial cell | 5 studies | 41% ± 17% | |
connective tissue cell | 5 studies | 23% ± 8% | |
epithelial cell | 4 studies | 35% ± 19% | |
neuron | 4 studies | 27% ± 6% | |
luminal cell of prostate epithelium | 4 studies | 51% ± 12% | |
secretory cell | 4 studies | 29% ± 7% | |
endothelial cell of lymphatic vessel | 3 studies | 21% ± 2% | |
mast cell | 3 studies | 21% ± 6% | |
cholangiocyte | 3 studies | 48% ± 18% | |
muscle cell | 3 studies | 20% ± 5% | |
GABAergic neuron | 3 studies | 31% ± 11% | |
glutamatergic neuron | 3 studies | 30% ± 11% | |
pancreatic ductal cell | 3 studies | 64% ± 15% | |
abnormal cell | 3 studies | 23% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 16387.53 | 245 / 245 | 100% | 529.95 | 502 / 502 |
breast | 98% | 4346.25 | 450 / 459 | 94% | 101.07 | 1053 / 1118 |
pancreas | 95% | 3533.43 | 310 / 328 | 94% | 266.83 | 167 / 178 |
intestine | 95% | 4014.21 | 918 / 966 | 89% | 121.32 | 471 / 527 |
uterus | 100% | 7703.12 | 170 / 170 | 83% | 79.59 | 380 / 459 |
lung | 99% | 3397.77 | 572 / 578 | 80% | 76.75 | 922 / 1155 |
brain | 85% | 3823.00 | 2250 / 2642 | 89% | 44.03 | 624 / 705 |
thymus | 98% | 2201.04 | 640 / 653 | 70% | 32.18 | 423 / 605 |
esophagus | 77% | 3008.27 | 1116 / 1445 | 86% | 108.79 | 158 / 183 |
kidney | 89% | 2323.45 | 79 / 89 | 64% | 55.33 | 574 / 901 |
stomach | 62% | 1434.12 | 223 / 359 | 90% | 118.13 | 258 / 286 |
bladder | 76% | 2134.95 | 16 / 21 | 68% | 71.66 | 341 / 504 |
ovary | 86% | 2028.97 | 155 / 180 | 49% | 27.26 | 212 / 430 |
adrenal gland | 50% | 1442.56 | 130 / 258 | 62% | 59.71 | 142 / 230 |
skin | 74% | 1999.55 | 1345 / 1809 | 33% | 34.96 | 155 / 472 |
blood vessel | 100% | 17974.53 | 1335 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 5150.39 | 1195 / 1204 | 0% | 0 | 0 / 0 |
heart | 94% | 2893.19 | 813 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 56% | 38.00 | 25 / 45 |
spleen | 51% | 714.63 | 122 / 241 | 0% | 0 | 0 / 0 |
muscle | 48% | 857.16 | 383 / 803 | 0% | 0 | 0 / 0 |
liver | 4% | 77.17 | 10 / 226 | 17% | 31.23 | 68 / 406 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.84 | 1 / 29 |
eye | 0% | 0 | 0 / 0 | 3% | 0.83 | 2 / 80 |
peripheral blood | 1% | 10.14 | 6 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030521 | Biological process | androgen receptor signaling pathway |
GO_0060392 | Biological process | negative regulation of SMAD protein signal transduction |
GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0010008 | Cellular component | endosome membrane |
GO_0031901 | Cellular component | early endosome membrane |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0070412 | Molecular function | R-SMAD binding |
GO_0140311 | Molecular function | protein sequestering activity |
GO_0005515 | Molecular function | protein binding |
GO_0050699 | Molecular function | WW domain binding |
Gene name | PMEPA1 |
Protein name | Prostate transmembrane protein, androgen induced 1 Protein TMEPAI (Prostate transmembrane protein androgen induced 1) (Solid tumor-associated 1 protein) (Transmembrane prostate androgen-induced protein) |
Synonyms | STAG1 TMEPAI |
Description | FUNCTION: Functions as a negative regulator of TGF-beta signaling and thereby probably plays a role in cell proliferation, differentiation, apoptosis, motility, extracellular matrix production and immunosuppression. In the canonical TGF-beta pathway, ZFYVE9/SARA recruits the intracellular signal transducer and transcriptional modulators SMAD2 and SMAD3 to the TGF-beta receptor. Phosphorylated by the receptor, SMAD2 and SMAD3 then form a heteromeric complex with SMAD4 that translocates to the nucleus to regulate transcription. Through interaction with SMAD2 and SMAD3, LDLRAD4 may compete with ZFYVE9 and SMAD4 and prevent propagation of the intracellular signal . Also involved in down-regulation of the androgen receptor (AR), enhancing ubiquitination and proteasome-mediated degradation of AR, probably by recruiting NEDD4 . . |
Accessions | A2A2F5 Q66K30 Q969W9 ENST00000265626.8 [Q969W9-3] ENST00000414037.5 ENST00000395814.5 [Q969W9-3] ENST00000395816.7 [Q969W9-3] ENST00000341744.8 [Q969W9-1] ENST00000347215.8 [Q969W9-2] A2A2F4 ENST00000395819.3 |